DOI QR코드

DOI QR Code

Risk Factors for Stage IV Breast Cancer at the Time of Presentation in Turkey

  • Uyeturk, Ummugul (Department of Medical Oncology, Abant Izzet Baysal University, Faculty of Medicine) ;
  • Tatli, Ali Murat (Department of Medical Oncology, Van Training and Research Hospital) ;
  • Gucuk, Sebahat (Bolu Izzet Baysal Family Health Center) ;
  • Oksuzoglu, Berna (Department of Medical Oncology, Dr. Abdurrahman Yurtarslan Oncology Training and Research Hospital) ;
  • Ulas, Arife (Department of Medical Oncology, Ali Osman Sonmez Oncology Training and Research Hospital) ;
  • Avci, Nilufer (Department of Medical Oncology, Balikesir State Hospital) ;
  • Ozbay, Mehmet Fatih (Department of Medical Oncology, Van Training and Research Hospital) ;
  • Gunduz, Seyda (Department of Medical Oncology, Akdeniz University, Faculty of Medicine) ;
  • Akinci, Muhammed Bulent (Department of Medical Oncology, Yildirim Beyazit University, Faculty of Medicine) ;
  • Salim, Derya Kivrak (Department of Medical Oncology, Akdeniz University, Faculty of Medicine) ;
  • Sonmez, Ozlem Uysal (Department of Medical Oncology, Sakarya Training and Research Hospital) ;
  • Akdag, Fatma (Department of Medical Oncology, Abant Izzet Baysal University, Faculty of Medicine) ;
  • Ergenc, Hasan (Department of Medical Oncology, Sakarya Training and Research Hospital)
  • Published : 2013.12.31

Abstract

Background: Breast cancer (BC) is the one of the most common cancers in women. It is also a leading cause of death. Unfortunately, some patients initially present with distant metastases and are diagnosed with stage IV disease that is nearly always, by then, incurable. This retrospective analysis investigated the risk factors for stage IV BC that may underlie such late presentation. Materials and Methods: In all, 916 patients with BC who visited the medical oncology polyclinic of eight different centres in Turkeybetween December 2011 and January 2013 were analysed. Results: A total of 115 patients (12.6%) presented with stage IV disease. In univariate analysis; to comparing these with patients at other stages, no statistical difference was found for median diagnosis age or age at menarche (p=0.611 and p=0.820), whereas age at menopause and age at first live birth were significant (p=0.018 and p=0.003). No difference was detected in terms of accompanying diseases, use of oral contraceptives and hormone replacement therapy, smoking, alcohol consumption and the rate of family history of BC between the patients (p=0.655, p=0.389, p=0.762, p=0.813, p=0.229, p=0.737). However, screening methods were employed less often, the rate of illiteracy was higher, and the rate of other cancers was higher in patients with stage IV BC (p=0.022, p=0.022, p=0.018). No statistical difference was observed between the patients in terms of tumour histopathology, and status of oestrogen receptor, progesterone receptor, or human epidermal growth factor-2 receptor (p=0.389, p=0.326, p=0.949, p=0.326). Grade 3 tumours were more frequent in patients with stage IV disease (p<0.001). On multivariate analysis, risk factors for stage IV breast cancer at the time of presentation were found to be age at first live birth and educational level (p=0.003 and p=0.047). Conclusions: Efforts should be made to perform mammography scans, in particular, at regular intervals through national training programs for all women, particularly those with family histories of breast and other types of cancer, and to establish early diagnosis of BC long before it proceeds to stage IV. Additionally, women's education had better be upgraded. In order to make women aware of BC, national education-programmes must be organised.

References

  1. Banning M (2011). Black women and breast health: a review of the literature. Eur J Oncol Nurs, 15, 16-22. https://doi.org/10.1016/j.ejon.2010.05.005
  2. Burgess CC, Potts HW, Hamed H, et al (2006). Why do older women delay presentation with breast cancer symptoms? Psycho-oncol, 15, 962-8. https://doi.org/10.1002/pon.1030
  3. Chang J, Clark GM, Allred DC, et al (2003). Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer, 97, 545-53. https://doi.org/10.1002/cncr.11083
  4. Cheng J, Qiu S, Raju U, Wolman SR, Worsham MJ (2008). Benign breast disease heterogeneity: association with histopathology, age, and ethnicity. Breast Cancer Res Treat, 111, 289-96. https://doi.org/10.1007/s10549-007-9775-5
  5. Chlebowski RT, Kuller LH, Prentice RL, et al (2009). Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med, 360, 573-87. https://doi.org/10.1056/NEJMoa0807684
  6. Daniilidis A, Giannoulis C, Sardeli C, et al (2010). Pregnancyassociated breast cancer a review analysis. Eur J Gynaecol Oncol, 31, 485-90.
  7. De P, Neutel CI, Olivotto I, Morrison H (2010). Breast cancer incidence and hormone replacement therapy in Canada. J Natl Cancer Inst, 102, 1489-95. https://doi.org/10.1093/jnci/djq345
  8. Ermiah E, Abdalla F, Buhmeida A, et al (2012). Diagnosis delay in Libyan female breast cancer. BMC Res Notes, 5, 452. https://doi.org/10.1186/1756-0500-5-452
  9. Ghazali SM, Othman Z, Cheong KC, et al (2013). Non-Practice of breast self examination and marital status are associated with delayed presentation with breast cancer. Asian Pac J Cancer Prev, 14, 1141-5. https://doi.org/10.7314/APJCP.2013.14.2.1141
  10. Gullatte MM, Phillips JM, Gibson LM (2006). Factors associated with delays in screening of self-detected breast changes in African-American women. J National Black Nurses' Association, 17, 45-50.
  11. Hayes J, Richardson A, Frampton C (2013). Population attributable risks for modifiable lifestyle factors and breast cancer in New Zealand women. Intern Med J, 43, 1198-204 https://doi.org/10.1111/imj.12256
  12. Horn J, Asvold BO, Opdahl S, Tretli S, Vatten LJ (2013). Reproductive factors and the risk of breast cancer in old age: a Norwegian cohort study. Breast Cancer Res Treat, 139, 237-43. https://doi.org/10.1007/s10549-013-2531-0
  13. Iwasaki M, Tsugane S (2011). Risk factors for breast cancer: epidemiological evidence from Japanese studies. Cancer Sci, 102, 1607-14. https://doi.org/10.1111/j.1349-7006.2011.01996.x
  14. Jemal A, Bray F, Center MM, et al (2011).Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  15. Jimeno A, Amador ML, Gonzalez-Cortijo L, et al (2004). Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma. Cancer, 100, 1833-42. https://doi.org/10.1002/cncr.20204
  16. Johnson KC, Miller AB, Collishaw NE, et al (2011). Active smoking and secondhand smoke increase breast cancer risk: the report of the Canadian Expert Panel on Tobacco Smoke and Breast Cancer Risk (2009). Tob Control, 20, 2.
  17. Kilciksiz S, Yilmaz E, Yigit S, Baloglu A (2012). Cancer in elderly: A study of hospital-based cancer registry in the Western Turkey. Hippokratia, 16, 57-60.
  18. Kruk J, Czerniak U (2013). Physical activity and its relation to cancer risk: Updating the evidence. Asian Pac J Cancer Prev, 14, 3993-4003. https://doi.org/10.7314/APJCP.2013.14.7.3993
  19. Kruk J (2007). Association of lifestyle and other risk factors with breast cancer according to menopausal status: a case-control study in the Region of Western Pomerania (Poland). Asian Pac J Cancer Prev, 8, 513-24.
  20. Largillier R, Ferrero JM, Doyen J, et al (2008). Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol, 19, 2012-9. https://doi.org/10.1093/annonc/mdn424
  21. Lobbezoo DJ, van Kampen RJ, Voogd AC, et al (2013). Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat, 41, 507-14.
  22. Ma H, Bernstein L, Ross RK, Ursin G (2006). Hormone-related risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: results from a case-control and a case-case comparison. Breast Cancer Res, 8, 39.
  23. Macia F, Pumarega J, Gallen M, Porta M (2013). Time from (clinical or certainty) diagnosis to treatment onset in cancer patients: the choice of diagnostic date strongly influences differences in therapeutic delay by tumor site and stage. J Clin Epidemiol, 66, 928-39. https://doi.org/10.1016/j.jclinepi.2012.12.018
  24. Marino N, Woditschka S, Reed LT, et al (2013). Breast Cancer Metastasis: Issues for the Personalization of Its Prevention and Treatment. Am J Pathol, 183, 4.
  25. Mirkin S, Komm BS, Pickar JH (2013). Conjugated estrogens for the treatment of menopausal symptoms: a review of safety data. Expert Opin Drug Saf, [Epub ahead of print].
  26. Mohiuddin M, Gafur MA, Karim MR, et al (2012). Clinicopathological stages of carcinoma breast patient. Mymensingh Med J, 21, 238-45.
  27. Morrell S, Taylor R, Roder D, Dobson A (2012) . Mammography screening and breast cancer mortality in Australia: an aggregate cohort study. J Med Screen, 19, 6-34.
  28. Nelson HD, Tyne K, Naik A, et al (2009). Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med, 151, 727-37. https://doi.org/10.7326/0003-4819-151-10-200911170-00009
  29. Neutel CI, Morrison H (2010). Could recent decreases in breast cancer incidence really be due to lower HRT use?Trends in attributable risk for modifiable breast cancer risk factors in Canadian women. Can J Public Health, 101, 405-9.
  30. Njor S, Nystrom L, Moss S, et al (2012). Breast cancer mortality in mammographic screening in Europe: a review of incidence-based mortality studies. J Med Screen, 19, 33-41. https://doi.org/10.1258/jms.2012.012080
  31. Novelli F, Milella M, Melucci E, et al (2008). A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res, 10, 74.
  32. Puliti D, Zappa M (2012). Breast cancer screening: are we seeing the benefit? BMC Med, 10, 106. https://doi.org/10.1186/1741-7015-10-106
  33. Redig AJ, McAllister SS (2013). Breast cancer as a systemic disease: a view of metastasis. J Intern Med, 274, 113-26. https://doi.org/10.1111/joim.12084
  34. Reyes-Ortiz CA, Markides KS (2010). Socioeconomic factors, immigration status, and cancer screening among Mexican American women aged 75 and older. Health Care Women Int, 31, 1068-81. https://doi.org/10.1080/07399332.2010.499183
  35. Reynolds, (2013). Smoking and breast cancer. J Mammary Gland Biol Neoplasia, 18, 15-23. https://doi.org/10.1007/s10911-012-9269-x
  36. Roder D, Houssami N, Farshid G, et al (2008). Population screening and intensity of screening are associated with reduced breast cancer mortality: evidence of efficacy of mammography screening in Australia. Breast Cancer Res Treat, 108, 409-16. https://doi.org/10.1007/s10549-007-9609-5
  37. Ruiterkamp J, Voogd AC, Tjan-Heijnen VC, et al (2012). SUBMIT: Systemic therapy with or without up front surgery of the primary tumor in breast cancer patients with distant metastases at initial presentation. BMC Surg, 12, 5. https://doi.org/10.1186/1471-2482-12-5
  38. Schairer C, Li Y, Frawley P, et al (2013). Risk factors for inflammatory breast cancer and other invasive breast cancers. J Natl Cancer Inst, 105, 1373-84. https://doi.org/10.1093/jnci/djt206
  39. Talpur AA, Surahio AR, Ansari A, Ghumro AA (2011). Late presentation of breast cancer: a dilemma. J Pak Med Assoc, 61, 662-6.
  40. van Schoor G, Moss SM, Otten JD, et al (2011). Increasingly strong reduction in breast cancer mortality due to screening. Br J Cancer, 104, 910-4. https://doi.org/10.1038/bjc.2011.44
  41. Walker MJ, Mirea L, Cooper K, et al (2013). Impact of familial risk and mammography screening on prognostic indicators of breast disease among women from the Ontario site of the Breast Cancer Family Registry. Fam Cancer, [Epub ahead of print]
  42. Walsh L, Schneider U (2013). A method for determining weights for excess relative risk and excess absolute risk when applied in the calculation of lifetime risk of cancer from radiation exposure. Radiat Environ Biophys, 52, 135-45. https://doi.org/10.1007/s00411-012-0441-x
  43. Wang L, Liao WC, Tsai CJ, et al (2013). The effects of perceived stress and life style leading to breast cancer. Women Health, 53, 20-40. https://doi.org/10.1080/03630242.2012.732680
  44. Wells KJ, Roetzheim RG (2007). Health disparities in receipt of screening mammography in Latinas: a critical review of recent literature. Cancer Control, 14, 369-79. https://doi.org/10.1177/107327480701400407
  45. Worsham MJ, Raju U, Lu M, et al (2007). Multiplicity of benign breast lesions is a risk factor for progression to breast cancer. Clin Cancer Res, 13, 5474-9. https://doi.org/10.1158/1078-0432.CCR-07-0928
  46. Xue F, Willett WC, Rosner BA, Hankinson SE, Michels KB (2011). Cigarette smoking and the incidence of breast cancer. Arch Intern Med, 171, 125-33.
  47. Zhang CX, Ho SC, Cheng SZ, et al (2011). Effect of dietary fiber intake on breast cancer risk according to estrogen and progesterone receptor status. Eur J Clin Nutr, 65, 929-36. https://doi.org/10.1038/ejcn.2011.57

Cited by

  1. Stereotactic Vacuum-Assisted Core Biopsy Results for Non-Palpable Breast Lesions vol.15, pp.13, 2014, https://doi.org/10.7314/APJCP.2014.15.13.5171
  2. Relationship between Breast Cancer and Levels of Serum Thyroid Hormones and Antibodies: a Meta-analysis vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6643
  3. Clinicopathologic Features and Molecular Subtypes of Breast Cancer in Young Women (Age ≤35) vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6665
  4. Associations of Demographic and Socioeconomic Factors with Stage at Diagnosis of Breast Cancer vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1627
  5. Oral Contraceptives, Abortion and Breast Cancer Risk: a Case Control Study in Saudi Arabia vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3957